Marcos Escosa Bagé*
Department of Neurosurgery, CHIP Hospital Complex, Spain
*Corresponding Author: Marcos Escosa Bagé, Department of Neurosurgery, CHIP Hospital Complex, Spain.
Received: October 26, 2020; Published: January 22, 2021
In recent years, studies have brought to light preclinical evidence of the ability of cannabinoids to reduce tumor growth in animal models, and clinical trials have been designed to study this activity in patients with glioblastoma. The data in animal models show promising results. So far it has been seen that the administration of THC is safe, and can be carried out without psychoactive effects. These molecules act through receptors coupled to the G protein, which are part of the endocannabinoid system and which have been called CB1 and CB2. THC can attenuate tumor progression in some patients, and appears to have a positive effect on survival, similar to that generated by other chemotherapeutic agents. More trials are needed to validate this antitumor action, both in combination with other therapies, and independently. At this time there is not enough scientific evidence to be able to conclusively affirm that cannabinoid treatment can contribute improve current therapies given to patients with brain tumors or other types of tumors.
Keywords: Glioblastoma; Endocannabinoid System; Antitumor Therapy
Citation: Marcos Escosa Bagé. “Cannabinoid Therapy for Glioblastoma Treatment: A Review”. Acta Scientific Neurology 4.2 (2021): 10-16.
Copyright: © 2021 Marcos Escosa Bagé. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.